Cervical cancer

Last updated: April 18, 2023

Summarytoggle arrow icon

Cervical cancer is the third most common type of gynecological cancer in the US after endometrial and ovarian cancer. The mortality and incidence of cervical cancer have significantly declined since the introduction of routine Papanicolaou-test screening (Pap smear) and human papillomavirus (HPV) vaccination. The most common histological type of cervical cancer is squamous cell carcinoma. In most cases, it arises from infection with high-risk HPV. Consequently, the risk factors for cervical cancer are, for the most part, identical to those for HPV (e.g., early onset of sexual activity, multiple sexual partners, history of STDs, and immunosuppression). Affected individuals are typically asymptomatic during early stages of the disease. Advanced cervical cancer typically manifests with vaginal bleeding, pelvic pain, and/or lower back pain. The development of cervical carcinoma is preceded by a premalignant epithelial dysplasia called “cervical intraepithelial neoplasia” (CIN), a type of premalignant epithelial dysplasia. The premalignant stages are screened with HPV tests (HPV DNA tests) and cytological investigation (Pap smear). Pap smears detect atypical squamous or glandular cells and, in some cases, also permit grading underlying intraepithelial lesions as low-grade (CIN I) or high-grade (CIN II/CIN III), based on the degree of atypia. Recommendations for colposcopy, treatment, and surveillance are based on a patient's risk of developing CIN III or higher. This risk is determined by current screening results and past medical history (including unknown history). High-grade intraepithelial lesions warrant colposcopy with cervical biopsy to determine the grade of CIN and diagnose invasive cervical cancer. Lesions consisting of a high-grade CIN may be excised using conization. The treatment of invasive cervical cancer involves a combination of surgery, radiation therapy, and/or chemotherapy, depending on the stage of the disease. Given that most patients are asymptomatic at early stages, primary (i.e., vaccination) and secondary (i.e., screening) prevention are particularly important. In the US, primary HPV testing is recommended for individuals between the ages of 25–65 years every 5 years. If this type of testing is not available, individuals should be screened with co-testing (HPV testing combined with a Pap smear) every 5 years or with a Pap smear every 3 years. Vaccination against HPV is currently approved for individuals aged 9–26 years.

Epidemiologytoggle arrow icon

One in 161 female individuals in the US (∼ 0.6%) will develop cervical cancer during their lifetime. [1]

Cervical intraepithelial neoplasia (CIN), a precursor of cervical cancer, typically occurs in young adults (25–35 years).

Epidemiological data refers to the US, unless otherwise specified.

Etiologytoggle arrow icon

Human papillomavirus virus (HPV) infection

Risk factors

Clinical featurestoggle arrow icon

Patients are usually asymptomatic in the early stages and develop symptoms later in the course of the disease.

Always consider cervical cancer as a cause of postcoital bleeding.

Classificationtoggle arrow icon

Classification of cervical pathology results

Overview of pathology results
Report description Bethesda system CIN grading
Squamous cells
Normal NILM Normal/benign
Squamous atypia ASC-US Squamous atypia/benign with inflammation
Mild dysplasia LSIL CIN I (including HPV)
Moderate dysplasia HSIL CIN II
Severe dysplasia CIN III
Carcinoma in situ
Invasive cancer Squamous cell carcinoma (SCC) Invasive cancer
Glandular cells
Atypical glandular cells AGC CIN I/CIN II/CIN III

Bethesda system for reporting cervical cytology report

The Bethesda system is a classification system used to report the results of cytological screening of cervical cancer. [6]

Cervical biopsy report (CIN grading)

Cervical intraepithelial neoplasia (noninvasive disease) [7]

Invasive cervical cancer

Cervical carcinoma most commonly arises from metaplastic squamous cell epithelium in the transformation zone (see “Microscopic anatomy of the cervix” in “Female reproductive organs” for more information on the histology of the cervix).

Staging of invasive cervical cancer

Pretreatment staging is the most accurate way of determining the extent of the disease.

FIGO staging of cervical cancer [14]
FIGO staging Tumor location and spread

Frequency at presentation

0 (Tis)
  • < 1%
  • Tumor strictly confined to the cervix
  • IA: deepest invasion ≤ 5 mm
    • IA1: stromal invasion ≤ 3 mm
    • IA2: > 3 mm, deepest invasion ≤ 5 mm
  • IB: > 5 mm depth
    • IB1: visible lesion > 5 mm deep, ≤ 2 cm maximum diameter
    • IB2: visible lesion > 2 cm and ≤ 4 cm maximum diameter
    • IB3: > 4 cm maximum diameter
  • 47%
  • Tumor invades beyond the uterus, but not into the pelvic wall or lower third of the vagina
  • IIA: upper two-thirds of the vagina, no parametrial invasion
    • IIA1: visible lesion ≤ 4 cm in greatest dimension
    • IIA2: visible lesion > 4 cm in greatest dimension
  • IIB: with parametrial invasion
  • 28%
  • 21%
  • 4%

Management of abnormal cervical cancer screening tests and cancer precursorstoggle arrow icon

Overview [15]

  • New management guidelines for the US have been introduced in 2019 by the American Society of Colposcopy and Cervical Pathology (ASCCP). [15]
    • Recommendations are based on HPV-based screening results and personal medical history (e.g., age, precancer treatment, immunosuppression, previous screening and biopsy results)
    • Newly defined risk thresholds have been introduced to guide appropriate management.
    • Recommendations for colposcopy, treatment, and surveillance are now based on a patient's immediate and 5-year risk of developing CIN III or higher-grade CIN (adenocarcinoma in situ or invasive cervical cancer) and not solely on screening results.
      • Patients with a high risk of developing cervical cancer will need more frequent surveillance, colposcopy, and/or treatment.
      • Patients with a lower risk of developing cervical cancer can defer colposcopy and have longer surveillance interval follow-ups.
    • The primary goal of treatment is to prevent the development of invasive cancer through the excision of precancerous lesions (CIN III, AIS).
      • Treatment is generally recommended as soon as a precancerous lesion is identified, the risk for CIN III was used as the treatment threshold.
      • Observation is preferred for CIN I rather than treatment
      • Excisional treatment is the preferred option
    • Abnormal screening results: updated management for abnormal primary HPV screening
    • Surveillance
  • See “Management according to previous guidelines” below.

Management according to 2019 ASCCP risk guidelines [15]

  • Management guidelines recommend different clinical actions depending on the patient's immediate risk of CIN III, AIS, or invasive cervical cancer based on current and past screening results:
Management according to the immediate risk of CIN III or higher [15]
Classification Indications Management
Immediate risk of CIN III or higher is ≥ 60%
Immediate risk of CIN III or higher is 25–59%
Immediate risk of CIN III or higher is 4–24%
  • Patients with unknown screening history and one of the following
Immediate risk of CIN III or higher is < 4%
  • Surveillance frequency depends on the 5-year risk for developing CIN III, adenocarcinoma in situ, or invasive cervical cancer.
  • Risk ≥ 0.55%: surveillance screening in 12 months
  • Risk ≥ 0.15–0.54%: surveillance screening in 3 years
    • HPV-negative with ASC-US and unknown screening results
    • HPV-negative and unknown history
  • Risk < 0.15%: surveillance screening in 5 years

Management according to abnormal screening results

ASCCP management guidelines according to abnormal screening results
Results Age of patient: < 25 years Age of patient: ≥ 25 years
  • Routine screening
Specimen unsatisfactory for evaluation (no HPV/unknown result) or HPV-negative [15][16]


  • CIN I or less preceded by ASC-H or HSIL
    • Colposcopy and HPV-based testing every 6 months for up to 2 years
      • If positive: colposcopy
      • If negative: HPV-based testing in 12 months
      • If negative twice: HPV-based testing in 3 years
    • If CIN II or higher is not found after ASC-H or HSIL: review of pathology and colposcopic findings
  • CIN I diagnosed consecutively for a minimum of 2 years
    • Colposcopy and HPV-based testing every 6 months for up to 2 years
    • Excisional treatment



Follow-up of abnormal results

Management according to previous guidelines [17][18]

Previous guidelines were based on screening results (Pap smear or co-testing). The recommendations still apply if primary HPV testing required for screening according to the new guidelines is not available.



Diagnosticstoggle arrow icon

Cervical cancer screening tests consisting of Pap smear and/or HPV DNA testing are performed regularly to identify cancer precursors and early-stage cervical cancer. Further workup for cervical cancer may include expedited treatment and colposcopy with biopsy. (See “Management of abnormal cervical cancer screening tests and cancer precursors” below.)

Cervical cancer screening

  • The U.S. Preventative Services Task Force (USPSTF) guidelines were last updated in 2018 and differ from other associations' guidelines. The American College of Obstetricians and Gynecologists (ACOG) and the Society of Gynecologic Oncology (SGO) endorse these guidelines. For average-risk patients (asymptomatic, immunocompetent, and normal cervical cancer screening history), they include three screening strategies depending on age: [19][20]
    1. 21–29 years of age: Pap smear every 3 years
    2. 30–65 years of age any of the following:
  • New screening guidelines were introduced by the American Society of Colposcopy and Cervical Pathology (ASCCP), and the American Cancer Society (ACS) in 2020. For average-risk patients, they include three screening strategies: [15][21]
  • Routine screening intervals for asymptomatic individuals who do not require surveillance:
Overview of cervical cancer screening guidelines [15][19][20][21][22][23]
Pap smear

21–65 years of age every 3 years

25–65 years of age every 3 years
Pap smear with high-risk HPV testing (cotesting) 30–65 years of age every 5 years 25–65 years of age every 5 years
Primary HPV testing Does not apply 25–65 years of age every 5 years (preferred)
  • If > 65 years: no more testing required if the previous testing was negative
  • If high-risk (immunocompromised, HIV, or DES exposure) but average life-expectancy: continue screening
  • HIV diagnosis: pap smear twice in the first year after HIV diagnosis and annually thereafter
  • Cervical cancer surveillance: Follow-up testing performed at a shorter interval than for routine screening either using HPV primary testing or co-testing.
    • Indicated for individuals with abnormal results:
    • Frequency of retesting depends on the individual's screening results and calculated risk for developing cervical cancer: 12 months< 5 years
  • For patients with invasive disease detected during screening, further workup is recommended for staging, including:

Papanicolaou test (Pap smear/cervical cytology)

  • Description: a cytological screening test for cervical cancer in which a cell sample taken from the cervix is examined for cellular abnormalities that may be indicative of cervical cancer
  • Pap smear technique: A proper technique is essential for obtaining highly specific test results. ; [24]
    • To obtain the specimen, use a sterile speculum to visualize the cervix
    • Cleanse the cervix using a cotton pledget.
    • Visualize the transformation zone and, if possible, the squamocolumnar junction.
    • The specimen must be collected using a spatula or brush that is rotated by 360 degrees.
    • A thin layer of the specimen is uniformly applied to the labeled glass slide.
      • Immediate fixation
        • Using 95% ethyl alcohol (or spray fixative) to avoid drying
        • Hold the fixative spray 15–20 cm away from the slide and spray evenly.
      • Stain using Papanicolaou dye.
  • Indications: screening for cervical intraepithelial neoplasia and invasive cervical cancer in individuals 25–65 years of age
  • Screening interval
    • Perform every 3 years if done alone
    • Perform every 5 years as co-testing
  • Findings: Pap smear results the Bethesda system (see below)
  • Advantages: detects early cellular changes indicating a risk for the development of cervical cancer
  • Contraindications [25]

HPV DNA testing [16][26]

  • Description: a screening test for cervical cancer in which cells collected from the cervix are tested for infection with high-risk HPV types
    • The viral DNA or RNA is detected using PCR-based assays.
    • Assays can detect HPV through:
      • Direct genome detection
      • Amplification of HPV fragments
      • Amplification and genotyping of HPV 16 and HPV 18
  • Types
  • Indications: screening for cervical intraepithelial neoplasia and invasive cervical cancer in individuals 25–65 years of age
  • Screening interval: perform every 5 years with HPV primary test and co-test
  • Findings (dependent on the primary HPV test used)
    • Pool detection of cancer-associated HPV subtypes (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)
    • Specific report of presence or absence of HPV subtypes (e.g., 16, 18)

Colposcopy [27][28][29]

  • Description: a procedure using a colposcope to examine the cervix, vagina, vulva, and anus for precancerous lesions or abnormalities
    • The procedure allows magnified visualization of the epithelium to guide biopsy sampling for histologic diagnosis.
    • In case of referral due to previous abnormal cytology and HPV results, testing can be repeated during this procedure.
  • Indications [15]
  • Findings
  • Possibility to defer colposcopy (according to new guidelines): patients with a low risk for CIN III, adenocarcinoma in situ, or cancer [15]
    • Patients with minor screening abnormalities (e.g., positive HPV, but not high-risk subtypes, low-grade cytologic abnormalities after a negative HPV test or co-test)
    • Patients who have their colposcopy deferred should return after 12 months for a repeat HPV test or co-test.
  • Advantages: identification and early treatment of precancerous or cancerous lesions
    • Allows for closer visualization of cervical lesions (the squamocolumnar junction and all lesions must be completely visualized)
    • Allows for identification of precancerous and cancerous lesions using acetic acid
    • Allows for biopsy or excision of suspicious lesions

Cervical biopsy

Treatmenttoggle arrow icon

Treatment of invasive cervical cancer [34][35][36][37]

Treatment of invasive cervical carcinoma may involve surgery, chemotherapy, and/or radiation.

Surgical procedures

  • Indicated for early-stage cancer (FIGO stages IA1, IA2, IB1, IB2, IIA)
Overview of surgical procedures
Type of procedure Description Indications Complications
Diagnostic excision procedures (excisional therapy) Cold-knife conization and loop electrosurgical excision procedure (LEEP)
  • A procedure in which a cone of cervical tissue comprising both the ectocervix and endocervix is excised with either a scalpel (cold-knife conization) or a laser loop (LEEP)
    • Cone biopsy must include the entire transformation zone, as it is the most common site for squamous lesions (> 90% of precancerous lesions).
    • See “Female reproductive organs” for more information on the transformation zone.
  • Patients with stage IA cervical cancer with negative tumor margins and without lymphovascular involvement [38][39]
  • Carcinoma in situ
  • As a therapeutic option for HSIL (CIN II/CIN III)
  • Suspicion of invasive cervical cancer
  • Inconsistency between cytological screening test and biopsy results
  • Large cervical lesion (covers > 75% of cervix)
  • Lesion extending into the endocervical canal
  • If the entire lesion or squamocolumnar junction cannot be completely visualized on colposcopy
Expedited treatment
  • Treatment without previous colposcopic biopsy, typically performed with excision treatment (LEEP) for nonpregnant patients ≥ 25 years of age
  • Patients with stage IA2–IB cervical cancer who wish to conceive
  • After a prior supracervical hysterectomy
Pelvic exenteration [42]
  • Palliative alternative for patients with stage IVA cervical cancer, although the prognosis is poor
  • Persistent or recurrent cervical cancer limited to the pelvis
  • Surgical removal of the uterus
  • Types of hysterectomy (see table below)
    • Subtotal (supracervical excision)
    • Total/simple (excision of uterus and cervix)
    • Radical (en bloc excision with parametrium and upper vagina)
  • Patients with stage IA1– IIA cervical cancer
  • Hemorrhage
  • Bladder and intestinal damage
  • Infection
Types of hysterectomy [43]
Simple extrafascial hysterectomy Modified radical hysterectomy Radical hysterectomy
Removed structures
Vaginal margin
  • None
  • 1–2 cm
  • Upper ¼–⅓
Mobilized structures
Separated structures

Pharmacological treatment

Overview of treatment according to FIGO staging system

Treatment of invasive cervical cancer according to FIGO staging system [37][44]
FIGO stage Surgery Radiation/Chemotherapy

Complicationstoggle arrow icon

Direct complications of invasive cervical cancer

Complications of radiation therapy [47]

We list the most important complications. The selection is not exhaustive.

Prognosistoggle arrow icon

  • Cervical cancer has the best prognosis out of the three main gynecological cancers (ovarian, endometrial, and cervical cancer).
  • The survival rates decrease with increasing FIGO stage [49]
    • Stage 0: > 93%
    • Stage I: 93%
    • Stage II: 63%
    • Stage III: 35%
    • Stage IV: 16%
  • Patients without lymph node involvement have a very good prognosis, regardless of FIGO stage.
  • Main cause of death: uremia, often occurs secondary to bilateral ureteral obstruction.

Preventiontoggle arrow icon

The most important measures for primary prevention are HPV immunization and use of barrier protection (condoms) during sexual intercourse. See “ACIP immunization schedule” for details. [50][51][52]

Special patient groupstoggle arrow icon


Diagnosis of cervical cancer in pregnant patients

Avoid endocervical curettage in pregnant patients, as it increases the risk for preterm delivery, heavy bleeding, and trauma to the gestational sac. [54]

Treatment of cervical cancer in pregnant patients [53][55]

Treatment depends on the patient's wish to conceive in the future and carry pregnancy to term, stage of pregnancy, and stage of cancer.

  • Treatment of cervical intraepithelial lesions during pregnancy
    • LSIL/CIN I: can be postponed up to 6 weeks postpartum for review
      • Should be reviewed every 12 weeks after exclusion of invasive cervical cancer
      • Treatment during pregnancy is not recommended
    • Delay Pap smear until 6 weeks postpartum
    • Colposcopy is recommended after 4 weeks postpartum
  • Treatment of invasive cervical cancer
    • Termination of pregnancy is generally recommended in early-stage cervical cancer or advanced cervical cancer unless the patient wishes to carry the child to term (see table below).
    • Appropriate treatment should be initiated after delivery (6–8 weeks postpartum) in patients whose pregnancy was maintained.
Treatment of cervical cancer in pregnant patients according to FIGO stage
FIGO stage Early pregnancy (< 22–25 weeks of gestation) Late pregnancy (≥ 22–25 weeks of gestation)
Stage IA1
  • Tumor diameter < 2 cm: postpone treatment until after delivery
Stage IA2–IB1
Stage IB2, IB3, or II

Referencestoggle arrow icon

  1. National Cancer Institute - Annual report to the nation (rates are age-adjusted and based on 2013–2017 cases and 2014–2018 deaths). . Accessed: October 8, 2020.
  2. Key Statistics for Cervical Cancer. Updated: January 8, 2019. Accessed: September 24, 2019.
  3. Gao Y, Ma J, Gao F, Song L. The evaluation of older patients with cervical cancer. Clin Interv Aging. 2013: p.783.doi: 10.2147/cia.s45613 . | Open in Read by QxMD
  4. Human papillomavirus (HPV) and cervical cancer.,and%20pre%2Dcancerous%20cervical%20lesions.. Updated: November 11, 2020. Accessed: November 12, 2020.
  5. Tomi Akinyemiju, Kemi Ogunsina, Swati Sakhuja, Valentine Ogbhodo, and Dejana Braithwaite. Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO's Study on Global Ageing and Adult Health (SAGE). BMJ Open. 2016.
  6. Updated Cervical Cancer Screening Guidelines. Updated: April 1, 2021. Accessed: July 29, 2021.
  7. USPSTF A and B Recommendations.. Updated: September 1, 2019. Accessed: October 7, 2019.
  8. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020; 70 (5): p.321-346.doi: 10.3322/caac.21628 . | Open in Read by QxMD
  9. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020; 24 (2): p.102-131.doi: 10.1097/lgt.0000000000000525 . | Open in Read by QxMD
  10. Updated Guidelines for Management of Cervical Cancer Screening Abnormalities. Updated: October 1, 2020. Accessed: April 12, 2021.
  11. Curry SJ, Krist AH, et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320 (7): p.674-686.doi: 10.1001/jama.2018.10897 . | Open in Read by QxMD
  12. Kripke et al.. Pap Smear vs. HPV Screening Tests for Cervical Cancer. American Family Physician. 2008; 12.
  13. Cervical Cancer Screening Among Women by Hysterectomy Status and Among Women Aged ≥65 Years — United States, 2000–2010. Updated: January 4, 2013. Accessed: March 9, 2021.
  14. New recommendation for cervical cancer screening, using HPV test alone. Updated: January 8, 2015. Accessed: October 18, 2019.
  15. $Updated Consensus Guidelines for Managing Abnormal Cervical Cancer -- Screening Tests and Cancer Precursors.
  16. Wright TC. The New ASCCP Colposcopy Standards. J Low Genit Tract Dis. 2017; 21 (4): p.215.doi: 10.1097/lgt.0000000000000337 . | Open in Read by QxMD
  17. THE CERVIX: Colposcopy of the Uterine Cervix. . Accessed: October 12, 2020.
  18. Colposcopy and treatment of cervical intraepithelial neoplasia. . Accessed: January 27, 2021.
  19. Marina OC. Effects of acetic acid on light scattering from cells. J Biomed Opt. 2012; 17 (8): p.085002.doi: 10.1117/1.jbo.17.8.085002 . | Open in Read by QxMD
  20. Underwood M, Arbyn M, Parry-Smith W, De Bellis-Ayres S, Todd R, Redman CW, Moss EL.. Accuracy of colposcopy‐directed punch biopsies: a systematic review and meta‐analysis. BJOG: An International Journal of Obstetrics and Gynaecology. 2012.
  21. Tests for Cervical Cancer. Updated: November 16, 2016. Accessed: November 5, 2019.
  22. Apgar BS, Kaufman AJ, Bettcher C, Parker-Featherstone E.. Gynecologic Procedures: Colposcopy, Treatment of Cervical Intraepithelial Neoplasia, and Endometrial Assessment. American Family Physician. 2013.
  23. Cervical Cancer Treatment (PDQ®)–Patient Version. Updated: February 6, 2019. Accessed: November 4, 2019.
  24. $FIGO Cancer Committee Guidelines for Early Invasive Cervical Cancer Management.
  25. World Health Organization. Comprehensive Cervical Cancer Control: A Guide to Essential Practice.. World Health Organization ; 2016
  26. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2018; 143: p.22-36.doi: 10.1002/ijgo.12611 . | Open in Read by QxMD
  27. Mauricio Maza, Celina M. Schocken, Katherine L. Bergman, Thomas C. Randall, and Miriam L. Cremer. Cervical Precancer Treatment in Low- and Middle-Income Countries: A Technology Overview. Journal of Global Oncology. 2017.
  28. Danielle B. Cooper; Gary W. Menefee. Conization Of Cervix. StatPearls. 2019.
  29. Angela Cho, Sunwha Park, Soyun Park, Hye Sim Kang, Soon Sup Shim, Chul Min Park, and Sung Yob Kim. Hemoperitoneum: a complication of loop electrosurgical excision procedure. Obstetrics & Gynecology Science. 2019.
  30. Surgical Procedures: Radical Cervical Trachelectomy. Updated: December 2, 2015. Accessed: November 5, 2019.
  31. Surgery for Cervical Cancer. Updated: November 16, 2016. Accessed: November 5, 2019.
  32. Neerja Bhatla1, Daisuke Aoki, Daya Nand Sharma, Rengaswamy Sankaranarayanan4. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2018.
  33. Cervical Cancer Treatment. . Accessed: January 25, 2021.
  34. Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016; 27 (4): p.e43.doi: 10.3802/jgo.2016.27.e43 . | Open in Read by QxMD
  35. WebMD. Cancer-related anorexia/cachexia an ongoing challenge despite an increasing range of drug choices. Drug Ther Perspect. 2001; 17 (22).
  36. Radiation Therapy for Cervical Cancer. Updated: December 5, 2016. Accessed: October 21, 2019.
  37. Masaharu Hata,Izumi Koike, Etsuko Miyagi, Reiko Numazaki, Mikiko Asai-Sato, Hisashi Kaizu, Yuki Mukai, Shoko Takano, Eiko Ito, Madoka Sugiura, and Tomio Inoue. Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas. Oncotarget. 2017.
  38. Cervical Cancer - Survival rates. Updated: October 17, 2019. Accessed: October 21, 2019.
  39. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports. 2021; 70 (4): p.1-187.doi: 10.15585/mmwr.rr7004a1 . | Open in Read by QxMD
  40. Human Papillomavirus Vaccination. Updated: August 1, 2020. Accessed: April 12, 2021.
  41. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Updated: August 18, 2021. Accessed: April 30, 2022.
  42. Nitish Beharee, Zhujun Shi, Dongchen Wu, and Jinhua Wang. Diagnosis and treatment of cervical cancer in pregnant women. Cancer Medicine. 2019.
  43. Jason Wright. Cervical cancer in pregnancy. Obstetrics and Gynecology. 2017.
  44. Beharee N, Shi Z, Wu D, Wang J. Diagnosis and treatment of cervical cancer in pregnant women. Cancer Medicine. 2019; 8 (12): p.5425-5430.doi: 10.1002/cam4.2435 . | Open in Read by QxMD
  45. PDQ Adult Treatment Editorial Board. Cervical Cancer Treatment (PDQ®): Patient Version. PDQ Cancer information. 2002.
  46. NCCN clinical Practice Guidelines in Oncology: Cervical Cancer, Version 1.2016 . Updated: November 25, 2015. Accessed: January 17, 2017.
  47. Mello V, Sundstrom RK. Cervical Intraepithelial Neoplasia (CIN). StatPearls. 2020.
  48. Jun Gu, Chit Yaw Fu, Beng Koon Ng, Lin Bo Liu, Soo Kim Lim-Tan, and Caroline Guat Lay Lee. Enhancement of Early Cervical Cancer Diagnosis with Epithelial Layer Analysis of Fluorescence Lifetime Images. PLOS One. 2015.
  49. Cervix Carcinoma - Squamous Cell Carcinoma. Updated: November 4, 2017. Accessed: February 21, 2018.
  50. Zaino RJ. Glandular Lesions of the Uterine Cervix. Mod Pathol. 2000; 13 (3): p.261-274.
  51. Subrata Pal, Sritanu Jana, and Kingshuk Bose. Clear cell carcinoma of cervix in a postmenopausal woman: A case report. Journal of Mid-life Health. 2015.
  52. Mario M Leitao, Jr, MD, Oliver Zivanovic, MD. Small cell neuroendocrine carcinoma of the cervix. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: July 1, 2019. Accessed: October 15, 2019.
  53. V P. Small Cell Neuroendocrine Carcinoma of the Cervix: A Rare Entity. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2014.doi: 10.7860/jcdr/2014/6811.4036 . | Open in Read by QxMD
  54. Kaiser Jamil, Javeed Ahmad, Hajira Fatima and G. Suryanarayana Raju. Significance of CA 125 and CEA as Biomarkers in Assessing Progress of Treatment for Cervical Cancer. International Journal of Pharmaceutical Sciences and Research. 2014.
  55. Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology & Obstetrics. 2019; 145 (1): p.129-135.doi: 10.1002/ijgo.12749 . | Open in Read by QxMD
  56. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016.. AC Cancer J Clin. 2016; 66 (1): p.7-30.doi: 10.3322/caac.21332 . | Open in Read by QxMD
  57. Cancer Facts & Figures 2017. Updated: January 5, 2017. Accessed: August 23, 2019.
  58. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.. American Journal of Obstetrics and Gynecology. 2017.
  59. Mangal Mahajan, Rajesh Kuber, KR Chaudhari, Prashant Chaudhari, Pravin Ghadage, Rushikesh Naik. MR imaging of carcinoma cervix. Indian Journal of Radiology and Imaging. 2013.
  60. Han Deng, Eric Hillpot, Sumona Mondal, Kamal K. Khurana & Craig D. Woodworth. HPV16-Immortalized Cells from Human Transformation Zone and Endocervix are More Dysplastic than Ectocervical Cells in Organotypic Culture. Scientific Reports. 2018.
  61. Murat Öz, Nilüfer Çetinkaya, Elmas Korkmaz, Kerem Doğa Seçkin, Mehmet Mutlu Meydanlı, and Tayfun Güngör. Optimal cone size to predict positive surgical margins after cold knife conization (CKC) and the risk factors for residual disease. Journal Of The Turkish-German Gynecological Association. 2016.
  62. Vishuda Laengsri, Chotiros Plabplueng, Lertyot Treeratanapiboon. Cervical Cancer Markers: Epigenetics and microRNAs. Laboratory Medicine. 2018.
  63. $Loop Electrosurgical Excision Procedure (LEEP) and Cold Knife Conization.
  64. $Atlas of Colposcopy: Principles and Practice.
  65. Walter Prendiville, Rengaswamy Sankaranarayanan. Colposcopy and Treatment of Cervical Precancer. World Health Organization ; 2017
  66. Noller KL, Wagner AL. Colposcopy. The Global Library of Women's Medicine. 2009.doi: 10.3843/glowm.10019 . | Open in Read by QxMD
  67. Wentzensen N, Massad LS, Mayeaux EJ, et al. Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. J Low Genit Tract Dis. 2017; 21 (4): p.216-222.doi: 10.1097/lgt.0000000000000322 . | Open in Read by QxMD

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer